Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI-3406 |
Synonyms | |
Therapy Description |
BI-3406 binds to SOS1 thus prevents SOS1 interaction with Kras-GDP, resulting in inhibition of Kras downstream signaling and potential inhibition of tumor cell growth (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2019, Abstract PL06-01, PMID: 32816843). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI-3406 | HY-125817|EX-A3418|BI3406|BI 3406 | SOS1 Inhibitor 16 | BI-3406 binds to SOS1 thus prevents SOS1 interaction with Kras-GDP, resulting in inhibition of Kras downstream signaling and potential inhibition of tumor cell growth (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2019, Abstract PL06-01, PMID: 32816843). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61K | lung non-small cell carcinoma | predicted - resistant | BI-3406 | Preclinical - Cell culture | Actionable | In a preclinical study, BI-3406 treatment failed to inhibit growth of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 32816843). | 32816843 |
BRAF V600E | colorectal cancer | predicted - resistant | BI-3406 | Preclinical - Cell culture | Actionable | In a preclinical study, BI-3406 treatment failed to inhibit growth of colorectal cancer cells harboring BRAF V600E in culture (PMID: 32816843). | 32816843 |
BRAF T119S BRAF V600E | colorectal cancer | predicted - resistant | BI-3406 | Preclinical - Cell culture | Actionable | In a preclinical study, BI-3406 treatment failed to inhibit growth of colorectal cancer cells harboring BRAF V600E and BRAF T119S in culture (PMID: 32816843). | 32816843 |
NRAS G12D | ovarian cancer | predicted - resistant | BI-3406 | Preclinical - Cell culture | Actionable | In a preclinical study, BI-3406 treatment failed to inhibit growth of ovarian cancer cells harboring NRAS G12D in culture (PMID: 32816843). | 32816843 |
BRAF V600E | melanoma | predicted - resistant | BI-3406 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BI-3406 treatment failed to inhibit growth of KRAS wild-type melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 32816843). | 32816843 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|